Literature DB >> 18487227

Role of Valpha14+ NKT cells in the development of Hepatitis B virus-specific CTL: activation of Valpha14+ NKT cells promotes the breakage of CTL tolerance.

Hiroyasu Ito1, Kazuki Ando, Tetsuya Ishikawa, Toshinori Nakayama, Masaru Taniguchi, Kuniaki Saito, Michio Imawari, Hisataka Moriwaki, Takashi Yokochi, Shinichi Kakumu, Mitsuru Seishima.   

Abstract

CTLs are thought to be major effectors for clearing viruses in acute infections including hepatitis B virus (HBV). Persistent HBV infection is characterized by a lack of or a weak CTL response to HBV, which is thought to reflect tolerance to HBV antigens. In the present study, we found that alpha-galactosylceramide (alpha-GalCer), a ligand for Valpha14-positive NKT cells, strongly enhanced the induction and proliferation of HBV-specific CTLs by HBsAg. In HBsAg transgenic mice, which are thought to be tolerant to HBV-encoded antigens, administration of HBsAg or alpha-GalCer alone failed to induce HBsAg-specific CTLs, but they were induced by co-administration of both compounds. Furthermore, by limiting dilution analysis, we confirmed the existence of HBsAg-specific CTL precursors in the HBsAg transgenic mice immunized with HBsAg and alpha-GalCer. A blocking experiment using antibodies to cytokines and CD40 ligand showed that IL-2 and CD40-CD40L interaction mediate the enhancement of CTL induction caused by alpha-GalCer through NKT cell activation. Our results may open up a new method for clearing the virus from patients with persistent HBV infection.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18487227     DOI: 10.1093/intimm/dxn046

Source DB:  PubMed          Journal:  Int Immunol        ISSN: 0953-8178            Impact factor:   4.823


  24 in total

1.  NKT cells--an early warning system for HBV infection.

Authors:  Dale I Godfrey; Adam P Uldrich; Alan G Baxter
Journal:  Nat Med       Date:  2012-07-06       Impact factor: 53.440

2.  α-Galactosylceramide protects mice from lethal Coxsackievirus B3 infection and subsequent myocarditis.

Authors:  C Y Wu; Y Feng; G C Qian; J H Wu; J Luo; Y Wang; G J Chen; X K Guo; Z J Wang
Journal:  Clin Exp Immunol       Date:  2010-08-19       Impact factor: 4.330

Review 3.  NKT cells in liver diseases.

Authors:  Shasha Zhu; Huimin Zhang; Li Bai
Journal:  Front Med       Date:  2018-04-06       Impact factor: 4.592

Review 4.  Targeting the diverse immunological functions expressed by hepatic NKT cells.

Authors:  Caroline C Duwaerts; Stephen H Gregory
Journal:  Expert Opin Ther Targets       Date:  2011-05-13       Impact factor: 6.902

5.  Combination therapy with TLR7 agonist and radiation is effective for the treatment of solid cancer.

Authors:  Hiroyasu Ito
Journal:  Ann Transl Med       Date:  2016-03

6.  iNKT cells in chronic HBV: a balancing act.

Authors:  Maike Hofmann; Robert Thimme
Journal:  Hepatol Int       Date:  2016-05-24       Impact factor: 6.047

7.  Induction of hepatitis B virus surface antigen-specific cytotoxic T lymphocytes can be up-regulated by the inhibition of indoleamine 2, 3-dioxygenase activity.

Authors:  Hiroyasu Ito; Tatsuya Ando; Kazuki Ando; Tetsuya Ishikawa; Kuniaki Saito; Hisataka Moriwaki; Mitsuru Seishima
Journal:  Immunology       Date:  2014-08       Impact factor: 7.397

Review 8.  NKT cell immune responses to viral infection.

Authors:  Marlowe S Tessmer; Ayesha Fatima; Christophe Paget; Francois Trottein; Laurent Brossay
Journal:  Expert Opin Ther Targets       Date:  2009-02       Impact factor: 6.902

9.  Regulation of the induction and function of cytotoxic T lymphocytes by natural killer T cell.

Authors:  Hiroyasu Ito; Mitsuru Seishima
Journal:  J Biomed Biotechnol       Date:  2010-05-19

Review 10.  Intrahepatic regulation of antiviral T cell responses at initial stages of viral infection.

Authors:  Yuejin Liang; Zakari Kwota; Jiaren Sun
Journal:  Int Immunopharmacol       Date:  2016-07-25       Impact factor: 4.932

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.